317 related articles for article (PubMed ID: 19639193)
1. The association between genetic polymorphisms in CYP19 and breast cancer risk in Korean women.
Kim JY; Lee CS; Kim HO; Jo YH; Lee J; Jung MH; Baik HH; Choe W; Kang I; Yoon KS
Oncol Rep; 2009 Sep; 22(3):487-92. PubMed ID: 19639193
[TBL] [Abstract][Full Text] [Related]
2. CYP19 (TTTA)n polymorphism and breast cancer risk in Brazilian women.
Ribeiro FS; de Amorim LM; de Almeida Simão T; Mendonça GA; de Moura Gallo CV; Pinto LF
Toxicol Lett; 2006 Jun; 164(1):90-5. PubMed ID: 16406421
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews.
Raskin L; Lejbkowicz F; Barnett-Griness O; Dishon S; Almog R; Rennert G
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1617-23. PubMed ID: 19366906
[TBL] [Abstract][Full Text] [Related]
4. The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers.
Huang CS; Kuo SH; Lien HC; Yang SY; You SL; Shen CY; Lin CH; Lu YS; Chang KJ
Oncologist; 2008 Jul; 13(7):751-60. PubMed ID: 18614591
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants of CYP19 (aromatase) and breast cancer risk.
Kristensen VN; Harada N; Yoshimura N; Haraldsen E; Lonning PE; Erikstein B; Kåresen R; Kristensen T; Børresen-Dale AL
Oncogene; 2000 Mar; 19(10):1329-33. PubMed ID: 10713674
[TBL] [Abstract][Full Text] [Related]
6. A tetranucleotide repeat polymorphism in the CYP19 gene and breast cancer susceptibility in a Greek population exposed and not exposed to pesticides.
Dialyna I; Tzanakakis G; Dolapsakis G; Tsatsakis A
Toxicol Lett; 2004 Jun; 151(1):267-71. PubMed ID: 15177662
[TBL] [Abstract][Full Text] [Related]
7. Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population.
Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Ohtake N; Takei T; Nakata S; Hasumi M; Yamanaka H
Anticancer Res; 2003; 23(6D):4941-6. PubMed ID: 14981949
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.
Tofteng CL; Kindmark A; Brändström H; Abrahamsen B; Petersen S; Stiger F; Stilgren LS; Jensen JE; Vestergaard P; Langdahl BL; Mosekilde L;
Calcif Tissue Int; 2004 Jan; 74(1):25-34. PubMed ID: 14517714
[TBL] [Abstract][Full Text] [Related]
9. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese.
Hirose K; Matsuo K; Toyama T; Iwata H; Hamajima N; Tajima K
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1407-11. PubMed ID: 15298966
[TBL] [Abstract][Full Text] [Related]
10. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.
Haiman CA; Hankinson SE; Spiegelman D; De Vivo I; Colditz GA; Willett WC; Speizer FE; Hunter DJ
Int J Cancer; 2000 Jul; 87(2):204-10. PubMed ID: 10861475
[TBL] [Abstract][Full Text] [Related]
11. The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women.
Baghaei F; Rosmond R; Westberg L; Hellstrand M; Eriksson E; Holm G; Björntorp P
Obes Res; 2003 Apr; 11(4):578-85. PubMed ID: 12690088
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival.
Boyapati SM; Shu XO; Ruan ZX; Cai Q; Smith JR; Wen W; Gao YT; Zheng W
Clin Cancer Res; 2005 Feb; 11(3):1093-8. PubMed ID: 15709176
[TBL] [Abstract][Full Text] [Related]
13. Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer.
Tsuchiya N; Wang L; Suzuki H; Segawa T; Fukuda H; Narita S; Shimbo M; Kamoto T; Mitsumori K; Ichikawa T; Ogawa O; Nakamura A; Habuchi T
J Clin Oncol; 2006 May; 24(13):1982-9. PubMed ID: 16648498
[TBL] [Abstract][Full Text] [Related]
14. The effect of CYP19 and COMT polymorphisms on exercise-induced fat loss in postmenopausal women.
Tworoger SS; Chubak J; Aiello EJ; Yasui Y; Ulrich CM; Farin FM; Stapleton PL; Irwin ML; Potter JD; Schwartz RS; McTiernan A
Obes Res; 2004 Jun; 12(6):972-81. PubMed ID: 15229337
[TBL] [Abstract][Full Text] [Related]
15. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk.
Miyoshi Y; Ando A; Hasegawa S; Ishitobi M; Yamamura J; Irahara N; Tanji Y; Taguchi T; Tamaki Y; Noguchi S
Eur J Cancer; 2003 Nov; 39(17):2531-7. PubMed ID: 14602139
[TBL] [Abstract][Full Text] [Related]
16. Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density.
Riancho JA; Zarrabeitia MT; Valero C; Sañudo C; Hernández JL; Amado JA; Zarrabeitia A; González-Macías J
Bone; 2005 May; 36(5):917-25. PubMed ID: 15794932
[TBL] [Abstract][Full Text] [Related]
17. Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women.
Dick IM; Devine A; Prince RL
Am J Physiol Endocrinol Metab; 2005 May; 288(5):E989-95. PubMed ID: 15613678
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk.
Healey CS; Dunning AM; Durocher F; Teare D; Pharoah PD; Luben RN; Easton DF; Ponder BA
Carcinogenesis; 2000 Feb; 21(2):189-93. PubMed ID: 10657957
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study.
Han DF; Zhou X; Hu MB; Xie W; Mao ZF; Chen DE; Liu F; Zheng F
Chin Med J (Engl); 2005 Sep; 118(18):1507-16. PubMed ID: 16232327
[TBL] [Abstract][Full Text] [Related]
20. Polymorphic variation in CYP19 and the risk of breast cancer.
Baxter SW; Choong DY; Eccles DM; Campbell IG
Carcinogenesis; 2001 Feb; 22(2):347-9. PubMed ID: 11181459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
